| Domain | Compact summary | Ontology / terminology suggestions | Evidence type | Caveats | Citations |
|---|---|---|---|---|---|
| Definition / onset | Primary congenital glaucoma (PCG) is the main primary childhood glaucoma subtype, usually presenting from birth to age 3 years, often within the first 6 months, due to developmental aqueous outflow abnormality causing elevated intraocular pressure (IOP), globe enlargement, and optic neuropathy. | MONDO:0018110; HPO onset suggestions: HP:0003577 Congenital onset, HP:0011463 Childhood onset | Disease review; genomics review; clinical perspective | Some sources discuss “childhood glaucoma” broadly; confirm whether a database entry should be restricted to isolated PCG versus broader primary childhood glaucoma. | (pqac-00000000, pqac-00000003, pqac-00000020) |
| Key identifiers | Suggested disease-level identifiers: MONDO:0018110; OMIM phenotype 231300 / GLC3A; ORPHA:98976; ICD-10 Q15.0; MeSH D005901. These are ontology metadata rather than patient-derived observations. | OMIM/Orphanet/ICD/MeSH/MONDO metadata | Curated ontology metadata | Verify against current ontology releases before KB ingestion; not all were evidenced in retrieved papers. | (pqac-00000001) |
| Epidemiology | Reported incidence/prevalence varies widely by ancestry and consanguinity: ~1 in 10,000–68,000 in Western countries; ~1:2500 in Saudi Arabia; ~1:8200 in Palestinian Arabs; ~1:1250 in Slovakian Gypsies. PCG contributes substantially to childhood blindness (about 5–18% globally; 4.2% cited in India). Bilateral disease occurs in ~70%, often asymmetrically. | HPO pattern suggestions: HP:0012837 Bilateral, HP:0012838 Unilateral, HP:0000628 Increased intraocular pressure | Epidemiology review; clinical review | Rates differ because of case definition, registry coverage, and referral bias. | (pqac-00000001, pqac-00000003, pqac-00000020, pqac-00000021) |
| Principal genes / inheritance | Major PCG genes include CYP1B1 and LTBP2 (typically autosomal recessive), TEK and ANGPT1 (autosomal dominant), and FOXC1 in some developmental/anterior-segment cases; CYP1B1 is the most frequently implicated gene overall and shows marked population-specific prevalence. SVEP1 has evidence as a modifier of TEK-related disease. | Gene symbols: CYP1B1, LTBP2, TEK, ANGPT1, FOXC1, SVEP1; inheritance: AR, AD | Human genetics review; human cohort genomics; model-supported modifier evidence | Genetic architecture is heterogeneous; many cohorts remain unsolved and inheritance can appear complex/digenic in some families. | (pqac-00000000, pqac-00000002, pqac-00000006) |
| Hallmark phenotypes | Classic presentation includes epiphora, photophobia, blepharospasm, corneal edema/haze, enlarged corneal diameter, Haab striae, buphthalmos, myopic shift, elevated IOP, optic disc cupping/asymmetry, and later visual field/vision loss. | HPO suggestions: HP:0000627 Epiphora, HP:0000613 Photophobia, HP:0000652 Blepharospasm, HP:0007957 Corneal edema, HP:0001083 Buphthalmos, HP:0000518 Cataract not core/if present assess secondary causes, HP:0000540 Hypermetropia not typical, HP:0000602 Ophthalmoplegia not typical, HP:0000598 Abnormality of the optic disc, HP:0007686 Increased cup-to-disc ratio, HP:0000541 Myopia, HP:0007906 Haab striae | Clinical review; disease review | Frequency of each sign varies with age at detection and severity; phenotype overlap with secondary childhood glaucoma is common. | (pqac-00000001, pqac-00000020, pqac-00000021) |
| Mechanism / anatomy | Core mechanism is developmental malformation of aqueous outflow pathways, especially trabecular meshwork and Schlemm canal. CYP1B1 dysfunction is linked to oxidative-stress and extracellular-matrix dysregulation in trabecular meshwork development; TEK/ANGPT1 signaling is crucial for Schlemm canal endothelial development; LTBP2 implicates extracellular matrix / TGF-β-associated structures; downstream consequence is elevated IOP with retinal ganglion cell injury and optic neuropathy. | GO suggestions: GO:0003151 outflow tract morphogenesis (approximate developmental analog; verify), GO:0030198 extracellular matrix organization, GO:0006979 response to oxidative stress, GO:0001525 angiogenesis, GO:0070934 CRYAB? verify before use, GO:0042060 wound healing not core; CL suggestions: trabecular meshwork cell, endothelial cell of Schlemm canal, retinal ganglion cell, neural crest-derived periocular mesenchymal cell; UBERON suggestions: UBERON:0001769 trabecular meshwork, UBERON:0010414 Schlemm canal, UBERON:0000924 cornea, UBERON:0000966 retina, UBERON:0001780 optic nerve | Human genetics review; mouse/zebrafish/cellular evidence | Several GO/CL/UBERON terms should be checked in the target ontology for exact preferred labels/IDs; zebrafish CYP1B1 models do not fully recapitulate human glaucoma. | (pqac-00000006, pqac-00000007, pqac-00000009, pqac-00000010, pqac-00000011) |
| Diagnosis | Diagnosis is clinical and often requires examination under anesthesia (EUA). Common criteria require childhood onset plus at least two features such as IOP >21 mmHg, glaucomatous optic nerve changes, corneal enlargement/Haab striae/edema, progressive myopia, or visual field defects. Gonioscopy is important; differential diagnosis includes megalocornea, keratoglobus, Peters anomaly, sclerocornea, and optic nerve hypoplasia. | HPO diagnostic features as above; NCIT-style test concepts: tonometry, gonioscopy, fundoscopy, axial length measurement, corneal diameter measurement | Clinical review; clinical perspective | Pediatric examination is difficult and often anesthesia-dependent; criteria differ somewhat across sources/CGRN adaptations. | (pqac-00000001, pqac-00000020, pqac-00000021) |
| Genetic testing | Gene panels, WES, and WGS can establish a molecular diagnosis, support counseling, and occasionally refine prognosis. In the Genomics England childhood glaucoma cohort, expanded analysis raised solved families to 26%; CYP1B1 accounted for 55% of solved families and novel TEK and FOXC1 variants/CNVs were identified. | Testing concepts: targeted glaucoma panel, WES, WGS, CNV analysis | Human cohort genomics; systematic review | Diagnostic yield remains incomplete; non-coding variants, CNVs, and panel limitations can reduce sensitivity. | (pqac-00000000, pqac-00000002) |
| Treatment algorithm | Surgery is the cornerstone. Initial treatment is usually angle surgery: goniotomy or trabeculotomy; combined trabeculotomy-trabeculectomy is often favored in severe edematous/megalocornea presentations in some regions. Refractory cases may need trabeculectomy with antifibrotics or glaucoma drainage devices; cyclodestructive procedures are generally reserved for poor-visual-potential/advanced cases. Medical therapy is supportive/temporary rather than definitive. | NCIT suggestions: Goniotomy, Trabeculotomy, Trabeculectomy, Glaucoma Drainage Device Implantation, Cyclophotocoagulation, Mitomycin C therapy | Clinical perspective; review; interventional trial registry | Surgical choice varies by corneal clarity, age, severity, and regional practice; high-quality randomized evidence remains limited. | (pqac-00000001, pqac-00000020, pqac-00000012, pqac-00000015, pqac-00000016, pqac-00000017) |
| Prognosis / outcomes | With timely treatment, prognosis can be favorable: stationary disease reported in 90.3% at 1 year, 70.8% at 10 years, and 58.3% at 34 years; median better-eye visual acuity reported as 20/30. Earlier presentation/intervention tends to improve angle-surgery success. Quality of life is reduced overall but tracks with visual acuity. | Outcome concepts: vision preservation, amblyopia prevention, low-vision rehabilitation | Review synthesis | Long-term results depend on age at diagnosis, corneal disease, surgical control, amblyopia management, and follow-up adherence. | (pqac-00000021, pqac-00000022) |
| Prevention / counseling | No general primary prevention is established for sporadic cases, but in high-risk/consanguineous families, genetic counseling, cascade testing, reproductive counseling, and early ophthalmic screening of relatives/newborns can reduce diagnostic delay and support family planning. Secondary prevention centers on rapid recognition of epiphora/photophobia/blepharospasm and urgent referral. | Counseling concepts: genetic counseling, carrier testing, cascade screening, prenatal/preimplantation options where locally available | Public-health review; genetics review; clinical perspective | Evidence is stronger for counseling/early detection than for population-wide screening programs. | (pqac-00000000, pqac-00000020) |
| Recent developments (2023–2024) | Notable recent advances include broader childhood-glaucoma genetic syntheses (2024), improved genome-analysis pipelines revealing missed TEK/FOXC1/CNV diagnoses (2024), and exploratory AI/deep-learning image models for pediatric glaucoma detection with reported sensitivity 0.85 and specificity 0.94. Multiple ongoing/recent PCG surgical trials compare trabeculotomy variants, adjunctive Ologen, and deep sclerectomy. | Methods terms: AI-assisted screening, WGS reanalysis, CNV detection | Recent reviews, genomics study, clinical trials | AI performance requires external validation; many trials are single-center and procedure-specific. | (pqac-00000000, pqac-00000021, pqac-00000015, pqac-00000016, pqac-00000017) |
| Models / comparative biology | Mouse models support CYP1B1-related trabecular meshwork defects and TEK/ANGPT1-dependent Schlemm canal development with IOP elevation and retinal ganglion cell loss. Zebrafish cyp1b1 knockout shows craniofacial/ECM phenotypes and incomplete penetrance but does not fully reproduce human glaucoma, highlighting species differences. | Model systems: mouse knockout/conditional models, zebrafish CRISPR knockout, endothelial cell assays | Model organism and in vitro evidence | Model validity is pathway-specific rather than full-phenotype complete. | (pqac-00000006, pqac-00000007, pqac-00000009, pqac-00000010) |


*Table: This table condenses the highest-yield disease characteristics for primary congenital glaucoma, including identifiers, genetics, mechanism, diagnosis, management, and models. It is designed as a compact curation aid and flags where ontology metadata or mechanistic interpretations should be verified before database ingestion.*